Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wish i knew, but for sure somebody does.Maybe they will announce the new biz direction?
Poppin! $KALY
Someone keeps buying... No news, should be .0001-0005
WHY????
Millions and Millions bought
$kaly $0.0015 ^ 0.0003 (25.00%)
Volume: 4,398,130 @01/29/21 3:37:15 PM EST
KALY Up 25% Today, It's Friday ! Have a good week-end !
etrade wont allow you to by this crap.. call the number its some bullshit....
yes call the company phone number its a joke///email them or call them ...this company a freaking crooked scam....they should be shut down now..
wow from covid to this hahaha What a frigging pump and dump scam
company crooked they dont have anything legit....
this piece of CRAP IS ran out of china....brokers ETRADE AND TD AMERITRADE WONT ALLOW YOU TO BUY THIS SCAM ...
Charles Yawn
Chairman, Kali Inc
CURRENT POSITION
Chairman, Kali Inc
TENURE AT CURRENT POSITION
12/2018-PRESENT
PREVIOUS POSITION
Chairman/CEO, Kali Inc
EDUCATION
--
BOARD MEMBERSHIPS
Kali Inc
INDUSTRY
Financial Services
CURRENT PRICE
KALY:US0.00USDAS OF 12:14 PM EST 01/11/2021SEE QUOTE
Board Memberships
TITLE
COMPANY
TENURE
Chairman
Kali Inc
PRESENT
Career History
TITLE
COMPANY
TENURE
Chairman/CEO
Kali Inc
UNKNOWN–12/2018
About Kali Inc
Kali, Inc. operates as a holding company. The Company, through its subsidiaries, invests in companies.
SECTOR
Financials
INDUSTRY
Financial Services
SUB-INDUSTRY
Asset Management
FOUNDED
10/30/2006
ADDRESS
Xiamen Guanyin Shan Intl Bldg Center, 5F, 151 Taidong Road Xiamen, 361008 China
CALL THE NUMBER IT A LIFE ALERT SYSTEM YOU WEAR AROUND YOUR NECK ..
ITS ALL BULL SHIT FOLKS THIS JIM DIPRIMA , SHOULD BE IN PRISON IMHO...
KALY DOESNT HAVE CRAP AGAIN CALL THE NUMBER ..THEIR FULL OF SHIT.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71636
> Dow Jones Newswires
January 08, 2021 11:44 ET (16:44 GMT)
THIS JIM IS SO FULL OF CRAP FOLKS CALL THE NUMBER ...
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71636
> Dow Jones Newswires
January 08, 2021 11:44 ET (16:44 GMT)
call the number at the bottom of the NEWS that was posted recently if you wanna good laugh this company doesnt have chit...
PAOG Confirms Q4 2020 Revenue from Cannabis Asset Acquisition
11:44 AM ET 1/8/21 | Dow Jones
Sandusky, Ohio--(Newsfile Corp. - January 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed that the Company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020.
In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT".
The hemp cultivation business came with an existing inventory that has been consigned to a retail sales operation. The existing inventory is valued at approximately $300,000 and PAOG expects to realize its first sales from the consigned inventory in Q4 2020.
PAOG has recently made substantial progress in advancing its business plan in conjunction with the two cannabis industry acquisitions and expects to publish a management update next week.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71636
> Dow Jones Newswires
January 08, 2021 11:44 ET (16:44 GMT)
$kaly $0.001 ^ 0.0001 (11.11%)
Volume: 4,550,269 @01/06/21 3:33:10 PM EST
Volume Alert
Someone picking up 10's a millions of shares between .0008-.0011
Question is WHY?
Can we get a press release letting shareholders know whats up?
this company nothing but a scam pile of shit ...crooks need to be in prison kaly done folks ...
Market ActivityStockKALYOverview
OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
ACCEPT
KALY
Kali, Inc.
Common Stock
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
Warning! This company may not be making material information publicly available
Buying or selling a security on the basis of material nonpublic material information is prohibited under Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b5-1 thereunder. Violators may be subject to civil and criminal penalties.
OTC Markets Group Inc. ("OTC Markets") has discontinued the display of quotes on www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware). OTC Markets Group designates certain securities as “Caveat Emptor” and places a skull and crossbones icon next to the stock symbol to inform investors that there may be reason to exercise additional caution and perform thorough due diligence before making an investment decision in that security.
The Caveat Emptor Designation may be assigned when OTC Markets becomes aware of one or more of the following:
Promotion — The security is the subject of stock promotion that may be misleading or manipulative. Promotional activities may include news releases, spam email, and newsletters, whether they are published by the issuer or a third party. See OTC Markets Group's Policy on Stock Promotion.
Investigation of Fraud or Other Criminal Activities — There is an investigation or other indication of fraudulent or other criminal activity involving the company, its securities or insiders.
Suspension/Halt — A regulatory authority or an exchange has halted or suspended trading for public interest concerns (i.e. not a news or earnings halt).
Undisclosed Corporate Actions — The security or company is the subject of a corporate action, such as a reverse merger, stock split, or name change, without adequate current information being publicly available.
Other Public Interest Concern — OTC Markets Group may determine that there is a public interest concern regarding the security. Such concerns may include but are not limited to promotion campaigns (including third-party), unusual or unexplained trading activity, spam or disruptive corporate actions even when adequate current information is available.
OTC Markets will resume the display of this security’s quotes once adequate current information is made available by the issuer pursuant to the Alternative Reporting Standard or by the SEC Reporting Standard, and until OTC Markets believes there is no longer a public interest concern. Investors are encouraged to use caution and due diligence in their investment decisions. Please read our Investor Protection page and OTC Markets Policy Regarding Caveat Emptor for more information.
CALL THE NUMBER ON THE BOTTOM THIS IS A PUCKING SCAM KALY CROOKED AND DIRTY.
PAOG Expects to Report First Post Acquisition Revenue in Q4 2020
12:17 PM ET 12/22/20 | Dow Jones
Sandusky, Ohio--(Newsfile Corp. - December 22, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced that the company expects to realize and report in Q3 2020 the first revenue from assets acquired in the course of 2020.
In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG recently announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). PAOG expects to realize its first revenue from the sale CBD nutraceuticals next year.
The hemp cultivation business came with an existing inventory that has been consigned to a retail sales operation. The existing inventory is valued at approximately $300,000 and PAOG expects to realize its first sales from the consigned inventory in Q4 2020.
Learn more about PRCCI at www.prcci.org.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70834
> Dow Jones Newswires
December 22, 2020 12:17 ET (17:17 GMT)
sorry but this company a scam .period ....its been a scam from the start ..all that bull chit news and it doesnt move.. again etrade and td ameritrade is not allowing their customers to buy it...
try again...
TDAmeritrade allows to buy any stocks with CE designation but only till January 31, 2021.
Then why does KALY sell 5 to 10 million shares a day, and recently sold 50 million shares over, a five day period?
TD is the most reputable firm correct their more stringent then etrade ....and both wont let you buy it...try again ..matter of fact why don't you posts your buy with kaly through td .... recent ones ...
I bought mine through td over 2 years ago then you had to call them . now you cannot buy under their firm ..
have them send you an email and prove me wrong then post it ....
I put their numbers out their and if you have a account with td then you already have it ....again I called today ...
your full of it call them ..I have had a td account since 1999...
neither td or etrade will allow you to buy it...
folks just called TD AMERITRADE AND OF COURSE HE LYING .
YOU CANT NOT BUY KALY YES THE CROOKED COMPANY ..
ETRADE OR TD AMERITRADE WILL NOT LET YOU BUY KALY THROUGH THEIR FIRM .
JUST ANOTHER BULL CRAP CON PERSON..
KALY DONE ....THESE CROOKS NEED TO BE IN PRISON....
AGAIN TD AMERITRADE OR ETRADE WILL NOT ALLOW YOU TO BUY KALY .
DONT BELIEVE CALL THEM THEY WONT LIE..
TD AMERITRADE 1-800-669-3900
ETRADE 1-800-387-2331
GO AHEAD AND COME UP WITH ANOTHER LIE....
ANYONE ELSE WANNA POSTS MORE LIES ABOUT THIS CROOKED COMAPN KALY..
Going for a ride.
I do have something legit to say.. I warned many investors here that this was SCAM For almost 2 years now and now one believed me... Well look at it.
empty shell.
SCAM
too funny post your order I also have td Ameritrade ... I had td since 1999.....td Ameritrade more of a stickler on stocks like kaly.
post your buy ... kaly a scam and they never return calls or emails ....until then people will know what kind of piece of chit kaly really is.....
dozens of emails and dozens of phone calls they never answer one . for several years....
this company is crooked ..period
I have plenty of money but will not see kaly burn more good people ...
you have something legit posts it...
Etrade is crap. I bought shares today at TD and the order went through, no problem. At the same time you can cool-it with the KALY bashing. Maybe you should change brokers?
company garbage you cant buy it with etrade they wont let you....
why because this company imho is crooked as hell...
these scums need to be in prison.
Going for a ride.
every time they put out crooked news as you all can see nobodys buying into their bull chit.....
fake company fake news.....what crooks this kaly is ...
all imho.
i call bull chit they dont have anything....
PAOG Expects to Report First Post Acquisition Revenue in Q4 2020
i expect this guys go to jail for fraud imho....
no website no legit number just a paid answering service...
THEY WILL NEVER CALL YOU BACK OR RETURN AN EMAIL....NOTHING BUT A FRAUD FROM MY DD...IMHO
ETRADE BROKER WONT ALLOW YOU TO BUY IT.....TRY IT AND CALL THEM THEY WILL VERIFY YOU CANT BUY IT THROUGH THEM..
ETRADE WILL NOT LET YOU BUY THIS CRAP.....THEY STOPPED THE BUYING ...MAYBE SOME BROKER IN A 3 RD WORLD COUNTRY WILL LET YOU BUY THIS SCAM....
KALY IS RAN OUT OF A SHACK IMHO....AGAIN CALL THE NUMBERS THEY WONT CALL YOU BACK.
THE NEWS THAT WAS JUST POSTED OUT ,,call the number at the bottom of todays news ...you want a good LAUGH CALL THE NUMBER ...ITS SOME BULL SHIT
more bull shit news these puckers dont have shit ..call the number it bogus . they will never ever call you back.....
this is a pure scam do your dd you will get burned from these crooks.
kaly a crooked piece of chit company..no legit phone number called dozens of time they dont return your call this has been a scam since day one the fucker need to be in prison....
all extensions are busy....again call many time company fake and crooked.
these fuckers will get delisted soon .....
kaly pure scum
Sec delisting caveat empire stocks. Get out of kali ASAP
and they shouldn't. Schwab just sent out a warning.
Caveat Emptor it is.
Got reading material for the ride. Liking KALY right now.
the number to some bull shit medical devise ,,,wow kaly at it again with their crooked bs scam..
again call the number below
PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution
12:19 PM ET 12/17/20 | Dow Jones
Sandusky, Ohio--(Newsfile Corp. - December 17, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
The Puerto Rico Consortium for Clinical Investigation (PRCCI) is a not-for-profit network of top performing, high-quality research sites invested in increasing the speed and quality of clinical trials. PRCCI enhances clinical research speed and quality by driving performance and efficiencies in research sites, leveraging strategic partnerships and by establishing world-class capabilities.
In addition to assisting PAOG with the laboratory development of CBD nutraceutical care solutions for those experiencing issues associated with COPD, PRCCI is also working to assist PAOG with expanding its hemp cultivation business in Puerto Rico. Earlier this year, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA). PRCCI is also working to assist PAOG in its partnership with PURA and Alkame Holdings, Inc. (OTC Pink: ALKM) to expand ALKM's co-packing operations in Puerto Rico in conjunction with the development of a CBD nutraceutical care solutions for those experiencing issues associated with COPD.
Learn more about PRCCI at www.prcci.org.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70541
> Dow Jones Newswires
December 17, 2020 12:19 ET (17:19 GMT)
hers another bull shit number call leave a message they will never return your call. .
every extensions they wont answer....these guys are freaking crooks..
don't believe call the number ,call these crooks they wont answer let alone return your call.
find this group of crooks and put them in prison imho..
Kali, Inc.
USOTC KALY
8300 Douglas Ave Suite 800, Dallas, TX 75225
214-210-0459
call this number complete joke....this from the news they put out today.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70541
> Dow Jones Newswires
December 17, 2020 12:19 ET (17:19 GMT)
folks call the number on the bottom of the news letter they just put out its a joke....dial that number ..
etrade wont let you buy this crooked shit. before you had to call etrade to but it now they wont even allow you to buy it...
KALY FUCKING CROOOKED BASTARDS.
We have continued bid support for some reason, would be nice to know if we get PAOG shares.
Is Kaly in business or is this a shell at this time?
Followers
|
315
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
32923
|
Created
|
01/26/09
|
Type
|
Free
|
Moderators |
GOLDMAN SMALL CAP RESEARCH REPORT AUTHORIZED: 5,000,000,000 OUTSTANDING: 1,276,240,706 RESTRICTED: 255,174,312 UNRESTRICTED: 1,021,066,394
KALI'S NEW BUSINESS PLAN With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates for wellness, edibles, and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022. Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon. NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Preclinical Research Study Results on Therapy for Respiratory Disease (COPD and Asthma) Below is a link to research recently conducted by Professor Jeffrey Osborn, President of Biomedical Science Research Group, LLC, and Biology Professor at the University of Kentucky Final Report for Pilot Study - NCMB-1 (aka Blue Dream)
LETTER TO SHAREHOLDERS FROM INCOMING CEO FREDERICK FERRI - NOVEMBER 27, 2018 Dear Kali Shareholders – |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |